* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Regulatory T cells and autoimmune diseases
Hygiene hypothesis wikipedia , lookup
Immune system wikipedia , lookup
Lymphopoiesis wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Adaptive immune system wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Molecular mimicry wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Th17 and Treg in RA Seong Wook Kang Division of Rheumatology Department of Internal Medicine Chnungnam National University School of Medicine Rheumatoid Arthritis Rheumatoid Arthritis (RA) • A symmetric polyarticular arthritis • Primarily affects the small joints of the hands and feet • Inflammation in the synovium • Pannus invades and destroys local articular structures Normal Synovium Pathogenesis of RA Role of T cells in RA • Prominent T-cell infiltrate in RA synovium • Genetic similarities between RA patients – specific human leukocyte antigen (HLA)-DR genes HLA DR4, DR14 and DR1 • Shared epitope – the third hypervariable region of DR β chains, especially amino acids 70 through 74 HLA Class II Molecule T cell antigen HLA class II molecule Antigen presenting cell Maturation of lymphocytes Routes of antigen entry Activation of naive and effector T cells by antigen from thymus Activated T cells deliver signals back to the APCs, further enhancing their ability to activate T cells Phases of T cell responses SIGNALS FOR T LYMPHOCYTE ACTIVATION • Proliferation of T lymphocytes and differentiation into effector and memory cells require – Antigen recognition – Costimulation – Cytokines that are produced by the T cells themselves and by APCs and other cells Differentiation of CD4+ T Cells into TH1, TH2, and TH17 Effector Cells Old versus new models of Th cell development Th17 cells • A novel lineage of CD4+ effector T helper (Th) cells which produce IL-17 – Murine models of autoimmunity: experimental autoimmune encephalomyelitis (EAE) and collageninduced arthritis (CIA) • Mediated by Th1 response (?): ablated by Ab for IL-12p40 • IL-23 shares with IL-12p40 – IL-12: p40 and p35 – IL-23: p40 and p19 • IL-23, not IL-12 is critically linked to autoimmunity in these models • IL-23 polarized cells express genes associated chronic inflammation, such as IL-17A, IL-17F, IL-6, TNF-a, and proinflammatory chemokines Main activities attributed to Th17 cells Diseases associated with Th17 Possible role of Th17 cells in RA • IL-17 and IL-23p19 were found in sera, synovial fluid, and synovial biopsies of most patients with RA • Increased expression of CC chemokine ligand 20 in the inflamed joints of patients with RA – CCL20 : able to bind CCR6 expressing Th17 cells • Increased number of Th17 cells were observed in the peripheral blood and the SF of RA patients Role of Th17 cells in RA Helper T cell (Th) subgroups Autoimmunity and Tolerance • Breakdown of self-tolerance: autoimmune disease – T cell compartment of the immune system can react with a variety of antigens • • • Equipped with receptors that are able to interact with self–antigens Auto-reactive T cell: potentially dangerous by initiating autoimmune responses Protective immune responses need to be stopped or down-regulated – When the body-invading agent has been neutralized – Intensity or chronicity may become dangerous for the body • Regulatory mechanisms are required – Thymic clonal deletion: apoptotic cell death (central tolerance) – Induction of anergy: functional inactivation – Activation-induced cell death – Suppression by regulatory lymphocytes: Role of FOXP3+ regulatory T cells (Treg) T cells suppressing immune responses • Described early 1970s by Gershon and Kondo • In mid-1990s, Sakaguchi identified a subset of CD4+ CD25+ T cells critical for preventing autoimmunity – when CD4+ T cells depleted of CD25+ T cells from normal mice were transferred into syngeneic athymic nude mice, multiorgan autoimmune disease was induced – Prevented by co-transfer of CD4+ CD25+ T cells Sakaguchi S. J Immunol 1995 Discovery of FOXP3 • FOXP3 (forkhead family transcription factor) – A critical regulator of Treg development, function, and homeostasis • FOXP3+ T cells, most of which are CD4+ CD25+ – suppress activation, proliferation and effector functions of immune cells including CD4+ and CD8+ T cells, NK cells, NKT cells, B cells and APCs – central in the prevention of autoimmune disease, allergy, and maintenance of allograft tolerance FOXP3+ regulatory T cells in human immune system • Treg expressing FOXP3 are indispensable for the maintenance of self tolerance and immune homeostasis • Genetic mutations in FOXP3 develop a severe, fatal systemic autoimmune disorder – IPEX (Immune dysregulation Polyendocrinopathy Enteropathy X-linked) syndrome • Enlargement of lymphoid organ, insulin-dependent diabetes, eczema, food allergy and concomitant infection Regulatory T cells • Many cell types have been shown to possess the capacity to regulate immune responses – CD4+CD25high regulatory T cells (“Tregs”), CD4+ Tr1 cells, CD4+ Th3 cells, CD8+CD28− T cells, CD4−CD8− T cells and NKT cells Characteristics of regulatory T cells Natural regulatory T cells (nTreg) vs. Induced Treg (iTreg) • Natural regulatory T cells (nTreg): Thymic-derived – One of the best-characterized subsets of immune regulatory cells is the CD4+CD25+/high Tregs – FOXP3 appears to have emerged as the definitive marker for such Tregs • Induced Treg (iTreg) – More recent studies have shown that FOXP3 may also be induced in CD4+FOXP3– T cells in vivo during some immune responses Thymic and Peripheral Generation of FOXP3+ Treg Cells Mechanisms of FOXP3+ Treg cell mediated suppression (direct) Mechanisms of FOXP3+ Treg cell mediated suppression (indirect) Tregs in autoimmune diseases • No difference in the frequency of CD4+ CD25+ Tregs but reduced suppressive activity – Multiple sclerosis – Myasthenia gravis – Type 1 diabetes – Rheumatoid arthritis • Decrease in CD4+ CD25+ Tregs frequency in peripheral blood – SLE – Kawasaki disease – Autoimmune lymphoproliferative syndrome Tregs in human RA • Tregs in patients with RA appear to be present in normal numbers and to exhibit all of the features of Tregs, not only in phenotype but also in their suppression of T cell proliferation. • Circulating Tregs isolated from patients with active RA are unable to suppress the release of pro-inflammatory cytokines by activated T cells and monocytes • Reversal of Treg-suppressive defect by successful anti-TNF treatment Tregs and inflammation in RA • The frequency of Tregs was much greater in the synovial fluid than in peripheral blood – The inflammatory milieu increases the number of Treg cells in the inflamed joint, but impairs their function – TNFα in SF of RA abrogate the suppressive activity of CD4+CD25+ Tregs • Balance between Tregs and pathogenic Th17 cells at the site of inflammation – TGFβ and IL-6 secretion in rheumatoid synovium Reciprocal generation of Treg and Th17 cells Tregs can convert to Th17 cells • Treg and Th17 cells may differentiate from the same precursor T cells – The balance of TGFβ and IL-6 might determine the differentiation of Treg / Th17 cells • The propensity of Tregs to convert to Th17 cells in the context of pro-inflammatory stimuli – FOXP3+CD4+ T cells can express RORγt and has the capacity to produce IL-17 Balance between Th17 and Treg Therapeutic potential of Tregs • In vivo expansion of CD4+CD25+ Tregs – Anti-CD3 monoclonal Ab (type I DM) – CD28 superagonist • Ex vivo generation of CD4+CD25+ Tregs – Adoptive cell Therapy Clinical applications of Tregs Adoptive cell Therapy Cellular therapy in RA • Tregs may convert to pathogenic cells in human RA • Strategies for expansion and isolation of highly pure FOXP3+ Tregs to be used in cellular therapy Summary • A role for Th17 in RA – Inflammation – Cartilage destruction – Bone erosion • Tregs have a key role in immune homeostasis – Important functions in suppressing unwanted inflammatory responses toward self-antigens • Great potential to use these cells in a therapeutic regimen for the treatment of autoimmune diseases